Cardinal Health Caps Fiscal 2026 With a 20% Earnings Beat and a $5 Billion Buyback
Cardinal Health closed its fiscal year Tuesday morning with one of the larger profit beats of the season's final stretch. The drug distributor reported fiscal fourth-quarter adjusted earnings of $2.91 per share, 49 cents above the $2.42 analysts expected and up about 40% from $2.08 a year earlier, according to MarketBeat. Shares climbed $7.96 to $245.13 in midday trading, a gain of roughly 7% that made the stock one of the session's standout earnings winners, per Investrade.
The revenue line told a different story. Sales of $63.67 billion grew 5.8% year over year but landed about $1.48 billion short of the $65.15 billion consensus, MarketBeat reported. For a distribution business that runs on razor-thin margins across enormous volumes, the market clearly weighted the profit performance over the top-line shortfall.
There was an asterisk inside the beat. Roughly 31 cents of the upside came from a non-recurring tariff refund of about $100 million, per MarketBeat, meaning the underlying operational beat was closer to 18 cents than 49. Even adjusted for that one-time item, the quarter cleared expectations, driven by the company's core Pharmaceutical and Specialty Solutions segment, where profit rose 21% from a year earlier.
What propelled the stock was less the quarter than the outlook. Cardinal guided fiscal 2027 adjusted earnings to a range of $12.40 to $12.60 per share, which the company framed as growth of 13% to 15% from a normalized fiscal 2026 base, with Pharmaceutical and Specialty Solutions profit projected to grow 8% to 11%, according to MarketBeat. CNBC's Investing Club called the profit outlook rosy and said it was raising its price target on the stock following the report.
Capital returns sweetened the package. The board approved a new $5 billion share repurchase authorization, with plans to buy back at least $1 billion of stock in fiscal 2027, and declared a quarterly dividend of $0.5158 per share, per MarketBeat. For a company whose investment case leans heavily on steady cash generation, the authorization signals confidence that the earnings trajectory in the guidance is durable.
The reaction fits this season's pattern in reverse. Companies that beat but merely reaffirmed guidance, such as DaVita, or trimmed outlooks modestly, such as Insulet, have been sold aggressively in recent sessions. Cardinal paired its beat with a raise-equivalent: a forward growth framework above what the Street had penciled in. The 7% pop is the reward side of the same asymmetric grading that has punished more cautious management teams.
Cardinal was one of just nine S&P 500 companies scheduled to report this week as the season enters its long tail, per FactSet, whose data show 86% of index constituents beating earnings estimates this quarter. Wall Street's average price target on the stock stood near $251.73 with a Moderate Buy consensus before the report, according to MarketBeat, a gap the Tuesday rally went most of the way toward closing.
